Please assess the completion status of the following clinical trial:

Trial Title: A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus and be at least 30 years of age~* Moderate or severe chronic renal insufficiency or end stage renal disease on dialysis~* Meet one of the following criteria:~  1. is currently not on an antihyperglycemic agent (AHA) and has A1C \>=7% and \<=10% at screening~ 2. is currently on a single oral AHA or low-dose dual oral combination AHA and has A1C \>=6.5% and \<=9% at screening~ 3. is currently on a stable insulin regimen (\>= 15 U/day) for \>= 10 weeks, with no oral AHA, and has A1C \>=7.5% and \<=10% and FPG \>130 mg/dL at screening~* (1) Male; (2) female not of reproductive potential; or (3) female of reproductive potential who agrees to remain abstinent or use alone or in conjunction with their partner 2 methods of contraception to prevent pregnancy during the study and for 28 days after the last dose of study drug~Exclusion Criteria:~* History of type 1 diabetes mellitus or a history of ketoacidosis~* Treated with any incretin mimetic or thiazolidinedione (TZD) within 12 weeks prior to screening or with omarigliptin at any time prior to study participation~* History of hypersensitivity to a dipeptidyl peptidase IV (DPP-4) inhibitor~* History of intolerance or hypersensitivity to glipizide or insulin glargine or any contraindication to glipizide or insulin glargine~* On a weight loss program and is not in the maintenance phase, or has been on a weight loss medication in the past 6 months, or has undergone bariatric surgery within 12 months prior to study participation~* Undergone a surgical procedure within 4 weeks prior to screening or has planned major surgery during the trial~* On or likely to require treatment for \>=2 consecutive weeks or repeated courses of corticosteroids (note: inhaled, nasal or topical corticosteroids are permitted)~* Currently being treated for hyperthyroidism or is on thyroid replacement therapy and has not been on a stable dose for at least 6 weeks~* If on dialysis, does not regularly adhere to dialysis schedule~* Diagnosis of congestive heart failure with New York Heart Association (NYHA) Class IV~* Medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease~* Human immunodeficiency virus (HIV)~* New or worsening coronary heart disease, congestive heart failure, myocardial infarction, unstable angina, coronary artery intervention, stroke, or transient ischemic neurological disorder within the past 3 months~* Poorly controlled hypertension~* Severe active peripheral vascular disease~* History of malignancy \<=5 years prior to study participation, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer~* Clinically important hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)~* Positive pregnancy test~* Pregnant or breast-feeding, or is expecting to conceive or donate eggs during the trial, including 28 days following the last dose of study drug~* User of recreational or illicit drugs or has had a recent history of drug abuse or routinely consumes \>2 alcoholic drinks per day or \>14 alcoholic drinks per week, or engages in binge drinking

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omarigliptin (Phase A) → Omarigliptin (Phase B) (Type: EXPERIMENTAL): Phase A: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 24 weeks. Phase B: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive matching placebo to glipizide daily in a blinded manner during Phase B of the study (Week 24 through Week 54).
- Placebo to omarigliptin (Phase A) → Glipizide (Phase B) (Type: ACTIVE_COMPARATOR): Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: matching placebo to omarigliptin orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive glipizide 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).

Based on this trial design, predict the completion outcome and termination type (if applicable).